Structure-based design of Mpro Antagonists

• Potent (IC50 sub-20nM) series of small molecule, non-peptidic, non-covalent, inhibitors of the SARS- CoV-2 main protease (Mpro) (Table 1).
• OCR8038 inhibitors have 0.2 μM activity in infected cells, while remdesivir is 1.0 μM
• Weak binding non-antiviral approved drug (Table 1/Cmpd 1) optimized for Mpro inhibition (Table 1/Cmpds 18 - 25).
• High-resolution co-crystal structures of complexes (Figure 1).
• Demonstrated anti-viral properties in vitro (Table 2).
• Synergy with remdesivir (Figure2)
• Drug-like properties & commercially viable synthetic routes